U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug develope r Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk.

Metsera accepted a sweetened offer from Pfizer late on Friday, citing U.S. antitrust risks in Novo’s bid that it had previously called superior. The Danish obesity drug behemoth said on Saturday it would exit the race.

The bidding war win hands Pfizer a way into the lucrative obesity drug market, even if Metsera’s treatments remain years from hitting the market. It marks a blow for Novo as it tries to claw back lost ground against U.S. rival Eli Lilly.

Twists and turns in a biotech bidding war

Pfizer appeared to have locked up the deal in September before Novo jumped in last week with

See Full Page